Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $83,995,132. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Tuesday, October 6th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.58, for a total transaction of $2,191,600.00.
• On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00.
• On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.24, for a total value of $2,144,800.00.
• On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00.

Halozyme Therapeutics Stock Down 0.9%

NASDAQ:HALO traded down $0.95 during trading hours on Thursday, hitting $109.84. 2,490,335 shares of the company’s stock traded hands, compared to its average volume of 2,620,154. The stock’s fifty day moving average price is $105.64 and its two-hundred day moving average price is $82.86. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $116.85. The firm has a market cap of $12.47 billion, a P/E ratio of 32.79, a P/E/G ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same period in the prior year, the company posted $1.54 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. CoreCap Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 98.0% in the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 150 shares in the last quarter. MRA Advisory Group bought a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $741,000. Congress Asset Management Co. boosted its stake in Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after buying an additional 1,052,509 shares in the last quarter. Cim Investment Management Inc. boosted its stake in Halozyme Therapeutics by 7.4% in the 2nd quarter. Cim Investment Management Inc. now owns 9,121 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 629 shares in the last quarter. Finally, QRG Capital Management Inc. grew its position in Halozyme Therapeutics by 11.1% in the second quarter. QRG Capital Management Inc. now owns 6,626 shares of the biopharmaceutical company’s stock valued at $519,000 after acquiring an additional 662 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Finally, Citizens Jmp lifted their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: A Dutch patent court found Merck’s subcutaneous Keytruda infringed a Halozyme patent and ordered MSD to stop manufacturing, selling, importing, or stocking the product in eight European markets: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The ruling could protect Halozyme’s intellectual-property position and potential royalty economics. Halozyme Wins Injunction Stopping Manufacture and Sale of Merck’s Keytruda SC in Multiple European Markets
• Positive Sentiment: Halozyme expanded its ENHANZE collaboration with argenx to cover two additional exclusive targets, bringing the total to eight. The agreement increases the opportunity for future development milestones and royalties and supports Halozyme’s recurring revenue growth. HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
• Neutral Sentiment: The Keytruda decision is a significant win, but the ongoing patent dispute, possible appeals, and the timing of any commercial impact create uncertainty around how quickly the ruling will translate into financial results.
• Negative Sentiment: JPMorgan raised its HALO price target from $70 to $78 but maintained a “neutral” rating. The new target implies roughly 29% downside from the referenced $109.84 price, signaling concern that the stock’s valuation already reflects much of its growth and legal upside. JPMorgan Raises Halozyme Price Target

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.